One-day DCF regimen in patients with metastatic gastric cancer


Dirican A., Kucukzeybek Y., Tarhan M. O., Somali I., Erten C., DEMİR L., ...Daha Fazla

TUMORI J, cilt.99, sa.2, ss.145-148, 2013 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 99 Sayı: 2
  • Basım Tarihi: 2013
  • Doi Numarası: 10.1700/1283.14183
  • Dergi Adı: TUMORI J
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.145-148
  • Eskişehir Osmangazi Üniversitesi Adresli: Hayır

Özet

Background. Cytotoxic chemotherapy is the basic treatment for metastatic gastric cancer. The "docetaxel, cisplatin, 5-day infusion of 5-FU (DCF5)" regimen is regarded as an effective therapy. However, the poor toxicity profile of this regimen and administration by 5-day infusion are major drawbacks of this method.